ViAqua Therapeutics, a biotechnology company and developer of an orally administered RNA-particle platform to promote and improve animal health in aquaculture, announced it has completed a $4.3 million round to commercialize and expand its platform. Multinational new investors include: S2G Ventures (S2G Oceans & Seafood Fund), Thai Union, and Agriline. Earlier investors Nutreco, Visvires New Protein, The Trendlines Group (SGX:42:T;OTCQX: TRNLY) and the Technion Israel Institute of Technology also participated in this round. ViAqua was also awarded additional grant funding from the Israeli Innovation Authority.